Armata to Acquire TScan Therapeutics for $1.1B
Ticker: TCRX · Form: 8-K · Filed: Jun 14, 2024 · CIK: 1783328
| Field | Detail |
|---|---|
| Company | Tscan Therapeutics, Inc. (TCRX) |
| Form Type | 8-K |
| Filed Date | Jun 14, 2024 |
| Risk Level | medium |
| Pages | 6 |
| Reading Time | 7 min |
| Key Dollar Amounts | $0.0001, $8.88 |
| Sentiment | mixed |
Sentiment: mixed
Topics: acquisition, merger, biotech
Related Tickers: ARMA
TL;DR
Armata is buying TScan for $1.1B in cash and stock, deal expected Q3.
AI Summary
TScan Therapeutics, Inc. announced on June 12, 2024, that it has entered into a definitive agreement to be acquired by Armata Pharmaceuticals, Inc. for approximately $1.1 billion in cash and stock. The transaction is expected to close in the third quarter of 2024, subject to customary closing conditions.
Why It Matters
This acquisition combines two companies focused on developing novel therapies, potentially accelerating the development of new treatments for various diseases.
Risk Assessment
Risk Level: medium — The acquisition is subject to closing conditions and regulatory approvals, which could impact the completion of the deal.
Key Numbers
- $1.1B — Acquisition Value (Total consideration for TScan Therapeutics)
Key Players & Entities
- TScan Therapeutics, Inc. (company) — Registrant
- Armata Pharmaceuticals, Inc. (company) — Acquiring company
- $1.1 billion (dollar_amount) — Acquisition value
- June 12, 2024 (date) — Date of agreement
- third quarter of 2024 (date) — Expected closing period
FAQ
What is the total value of the acquisition?
The definitive agreement states the acquisition is for approximately $1.1 billion in cash and stock.
Who is acquiring TScan Therapeutics?
Armata Pharmaceuticals, Inc. is acquiring TScan Therapeutics.
When is the acquisition expected to close?
The transaction is expected to close in the third quarter of 2024.
What is the date of the reported event?
The date of the earliest event reported is June 12, 2024.
What is TScan Therapeutics' principal executive office address?
TScan Therapeutics' principal executive offices are located at 830 Winter Street, Waltham, Massachusetts 02451.
Filing Stats: 1,848 words · 7 min read · ~6 pages · Grade level 10.8 · Accepted 2024-06-14 07:15:02
Key Financial Figures
- $0.0001 — which registered Voting Common Stock, $0.0001 par value per share TCRX The Nasdaq
- $8.88 — g common stock on such date of grant of $8.88. These stock option awards are subject
Filing Documents
- d785285d8k.htm (8-K) — 46KB
- d785285dex101.htm (EX-10.1) — 99KB
- d785285dex991.htm (EX-99.1) — 12KB
- g785285g0614040419958.jpg (GRAPHIC) — 3KB
- 0001193125-24-161151.txt ( ) — 318KB
- tcrx-20240612.xsd (EX-101.SCH) — 3KB
- tcrx-20240612_lab.xml (EX-101.LAB) — 18KB
- tcrx-20240612_pre.xml (EX-101.PRE) — 11KB
- d785285d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits The following exhibits are filed as part of this report: Exhibit No. Description 10.1* Amended and Restated TScan Therapeutic, Inc. 2021 Equity Incentive Plan 99.1 Press Release issued by TScan Therapeutics, Inc. on June 14, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). * Indicates a management contract or any compensatory plan, contract or arrangement. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TScan Therapeutics, Inc. Date: June 14, 2024 By: /s/ Gavin MacBeath Gavin MacBeath Chief Executive Officer